Additional Broker Option - Extension

Belluscura PLC
28 April 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK version of the Market Abuse Regulation (EU) No.596/2014, which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

 

Belluscura plc

 

("Belluscura", the "Company" or the "Group")

 

Additional Broker Option - Extension

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, provides an update further to its announcement on 10 February 2023 (headed "Result of Broker Option; Additional Broker Option").

 

Additional Broker Option

 

As announced on 10 February 2023, in addition to the $5.8 million (£4.7 million), before expenses raised in Loan Notes in the Placing and Broker Option, Dowgate had identified significant further potential demand for the Loan Notes from placees.

 

As a result, the Company agreed to issue an additional broker option ("Additional Broker Option") to enable Dowgate to arrange the placing of further loan notes to raise up to an additional approximately $4.2 million (£3.4 million) (the "Additional Broker Option Loan Notes"). This Additional Broker Option was originally scheduled to expire on 28 April 2023. Under the Placing Agreement the Long Stop Date for issuance of the Loan Notes is 12 May 2023, subject to agreement with Dowgate and SPARK.

 

Interest for significant further demand in the Loan Notes from prospective placees remains, however, Dowgate has advised the Company that these prospective placees require more time, and consequently the Company, Dowgate and SPARK have agreed to allow Dowgate to exercise the Additional Broker Option up to 16 June 2023 and any Additional Broker Option Loan Notes will be issued by the Company on 23 June 2023 with a revised Long Stop Date of 30 June 2023. Accordingly, the Placing Agreement and the Instrument were further amended and restated on 27 April 2023 to extend the deadlines related to the exercise of the Additional Broker Option and the issue of Additional Broker Option Loan Notes thereunder.

 

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released on 27 January 2023 and/or 10 February 2023 unless the context requires otherwise.

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman

Robert Rauker, Chief Executive Officer

Anthony Dyer, Chief Financial Officer


 


SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin


 


Dowgate Capital Limited

Broker and Bookrunner

Tel: +44 (0)20 3903 7715

James Serjeant / Russell Cook


 


MHP

Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

Katie Hunt/Pete Lambie/ Matthew Taylor

 email: Belluscura@mhpgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Belluscura (BELL)
UK 100

Latest directors dealings